![]() |
|
|
Vol. 54, Issue 1, 50-58, July 1998
Laboratory of Molecular Pharmacology, Division of Basic Sciences, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892-4255 (G.K., Y.P.), Information Technology Branch, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892 (K.D.P.), and Department of Chemistry and Molecular Pharmacology, Purdue University, West Lafayette, Indiana 47907-1333 (M.C., P.N.)
| |
Summary |
|---|
|
|
|---|
NSC 314622 was found to have a cytotoxicity profile comparable to the topoisomerase I (top1) inhibitors camptothecin (CPT) and saintopin in the National Cancer Institute In Vitro Anticancer Drug Discovery Screen using the COMPARE analysis. In vitro data showed that NSC 314622 induced DNA cleavage in the presence of top1 at micromolar concentrations. Cleavage specificity was different from CPT in that NSC 314622 did not cleave all sites induced by CPT whereas some sites were unique to the NSC 314622 treatment. Top1-induced DNA cleavage was also more stable than cleavage induced by CPT. NSC 314622 did not induce DNA cleavage in the presence of human topoisomerase II. High concentrations of NSC 314622 did not produce detectable DNA unwinding, which suggests that NSC 314622 is not a DNA intercalator. DNA damage analyzed in human breast carcinoma MCF7 cells by alkaline elution showed that NSC 314622 induced protein-linked DNA single-strand breaks that reversed more slowly than CPT-induced strand breaks. CEM/C2, a CPT-resistant cell line because of a top1 point mutation [Cancer Res 55:1339-1346 (1995)], was cross-resistant to NSC 314622. These results demonstrate that NSC 314622 is a novel top1-targeted drug with a unique chemical structure.
| |
Introduction |
|---|
|
|
|---|
CPT
derivatives have recently been introduced in the clinic and are among
the most promising novel anticancer drugs. The only known cellular
target of CPTs is mammalian DNA top1 [for reviews, see Chen and Liu
(1994)
and Pommier (1996)
]. Top1 plays an essential role in DNA
metabolism and its catalytic intermediates are DNA cleavage complexes
[for reviews see Champoux (1990)
, Gupta et al. (1995b)
,
Wang (1996)
, and Pommier (1998)
]. These cleavage complexes consist of
DNA single-strand breaks that are generated by top1 as the enzyme
cleaves the DNA and forms a covalent bond with the 3'-DNA termini.
Under physiological conditions, the cleavage complexes are reversible
and top1 religates the broken DNA. Camptothecin and its clinical
derivatives trap top1 cleavage complexes by inhibiting their religation
and as a consequence generate DNA damage.
The fact that camptothecins are active against solid tumors including ovarian and colon carcinomas and are the only class of top1 poisons used in the clinic to date prompted us to look for novel top1 inhibitors. Here we report a novel top1 poison, NSC 314622 (Fig. 1), with original structure and describe its molecular and cellular interactions with mammalian top1.
|
| |
Materials and Methods |
|---|
|
|
|---|
Synthesis of NSC 314622.
This compound was synthesized in
two steps from 4,5-dimethoxyhomphtalic anhydride and 3,4-methylenedioxy
benzylidenemethylamine according to our previously published procedure
(Cushman and Cheng, 1978
). The melting point and IR- and
1H-NMR spectra of the synthetic compound compared
favorably with the published data and were identical with those
produced by a reference sample on the same spectrometer at the same
time. NSC 314622 is a stable substance that displayed no signs of
decomposition when stored over long periods of time in the solid state.
Drugs, enzymes, and chemicals.
Camptothecin was obtained
from the Drug Synthesis and Chemistry Branch, National Cancer Institute
(Bethesda, MD). Drug stock solutions were made in DMSO at 10 mM and aliquots were stored at
20°. Further dilutions
were made in DMSO immediately before use. The final concentration of
DMSO in the reactions did not exceed 10% (v/v).
-32P]ATP,
[
-32P]deoxyCTP, and
[
-32P]cordycepin were purchased from
DuPont-New England Nuclear (Boston, MA). SV40, c-myc human DNA inserted
in pBR322, and oligonucleotides were purchased from GIBCO BRL, the
American Type Culture Collection (Rockville, MD), and Midland Certified
Reagent (Midland, TX), respectively.
Cell cultures.
The MCF7 cells were obtained from Dr. Dominic
Scudiero (Developmental Therapeutics Program, National Cancer
Institute, Frederick, MD). The CEM/C2 cell line was established as
described previously (Fujimori et al., 1995
, 1996
). Cells
were maintained in RPMI 1640 (GIBCO BRL, Gaithersburg MD) supplemented
with 10% fetal bovine serum (Atlanta Biologicals, Norcross, GA) and 2 mM L-glutamine in a 5%
CO2 incubator at 37°.
Top1-mediated DNA cleavage reactions using end-labeled
c-myc DNA, 161-bp plasmid DNA, and the top1
oligonucleotides.
The 401-bp DNA fragment from the human
c-myc proto-oncogene includes the junction between the first
intron and first exon. It was prepared by PCR using the sense primer
(oligo 2671-2692) and the antisense primer (oligo 3052-3072); the
numbers in parenthesis refer to the genomic position of the
corresponding base in c-myc DNA (Leteurtre et
al., 1994
). Single-end labeling was obtained by
32P-5'-end labeling of the sense primer. Twenty
picomoles of DNA were incubated for 30 min at 37° with 10 units of T4
polynucleotide kinase and 10 pmol of
[
-32P]ATP (approximately 100 µCi) in
kinase buffer (70 mM Tris·HCl, pH 7.6, 0.1 M
KCl, 10 mM MgCl2, 5 mM
dithiothreitol, and 0.5 mg/ml bovine serum albumin). Reactions were
stopped by heat denaturation at 70° for 10 min. Five picomoles of the
labeled primer and 10 pmol of the antisense primer (unlabeled) were
used for the PCR. Approximately 0.1 µg of the c-myc plasmid that had
been cleaved with SmaI and SacI was used as a
template during the 22 temperature cycle reactions (each cycle: 95°
for 1 min, 56° for 1.5 min, and 72° for 2 min). The last extension
was for 7 min. DNA was purified using a G-50 quick spin column
(Boehringer-Mannheim Biochemicals, Indianapolis, IN). The resulting
401-bp PCR fragment corresponded to the human c-myc DNA
region between positions 2671 and 3072, according to the GenBank
numbers. This fragment was used to assay top1-induced DNA cleavage by
CPT or NSC 314622. Top1 reactions were performed at 30° for 30 min in
the presence of CPT or NSC 314622. The same volume of DMSO used in the
drug-treated samples was added to the reactions without drug. Reactions
were terminated by adding 0.5% SDS followed by digestion with 0.5 mg/ml proteinase K for 60 min at 50°. Reversibility of cleavage
complexes was tested by adding 0.5 M NaCl 15 min before
terminating the reactions.
) phagemid DNA (Stratagene,
La Jolla, CA) was cleaved with the restriction endonucleases PvuII and HindIII (New England Biolabs, Beverly,
MA) in supplied NE buffer 2 (50-µl reactions) for 1 hr at 37°,
separated by electrophoresis in a 1% agarose gel made in 1 × TBE
buffer. The 161-bp fragment was eluted from the gel slice (centrilutor
by Amicon, Beverly, MA) and concentrated in a centricon 50 centrifugal
concentrator (Amicon). Approximately 200 ng of the fragment was 3'-end
labeled at the HindIII site by fill-in reaction with
[
-32P]dCTP and 0.5 mM dATP,
dGTP, and dTTP, in REact 2 buffer (50 mM Tris·HCl, pH
8.0, 100 mM MgCl, and 50 mM NaCl; New England Biolabs) with 0.5 units of DNA polymerase I (Klenow fragment). Labeling
reactions were followed by phenol/chloroform extraction and ethanol
precipitation. The resulting 161-bp 3'-end-labeled DNA fragment was
resuspended in water. Aliquots (approximately 50,000 dpm/reaction) were
incubated with top1 at 30° for 15 min in the presence of NSC 314622 or CPT. Reactions were terminated by adding 0.5% SDS. After ethanol
precipitation the samples were resuspended in loading buffer (80%
formamide, 10 mM sodium hydroxide, 1 mM sodium
EDTA, 0.1% xylene cyanol, and 0.1% bromphenol blue, pH 8.0), and
separated in a denaturing gel (16% polyacrylamide and 7 M
urea) run at 51°. The gel was dried and visualized by using a
PhosphorImager and ImageQuant software (Molecular Dynamics, Sunnyvale,
CA).
The DNA oligonucleotide with a single top1 cleavage site (Pommier
et al., 1995
-32P]cordycepin and terminal transferase,
as described previously (Pommier et al., 1995SV40 DNA unwinding assay.
Reaction mixtures (10 µl final
volume) contained 0.3 µg supercoiled SV40 DNA in reaction buffer (10 mM Tris·HCl, pH 7.5, 50 mM KCl, 5 mM MgCl2, 0.1 mM EDTA,
and 15 µg/ml bovine serum albumin) and 10 units of purified calf
thymus top1 (Pommier et al., 1987
). Reactions were performed
at 37° for 30 min and terminated by the addition of 0.5% SDS. Next,
1.1 µl of 10× loading buffer (20% Ficol 400; 0.1 M
Na2EDTA, pH 8.0, 1.0% SDS, and 0.25% bromphenol blue) was added and reactions mixtures were loaded onto a 1% agarose gel made in 1 × TBE buffer. After electrophoresis, DNA bands were stained in 10 µg/ml of ethidium bromide and visualized by
transillumination with ultraviolet light (300 nm).
Top1-mediated DNA relaxation assays. Reactions were performed in a 10-µl final volume at 37° in reaction buffer (see above) with 0.3 µg supercoiled SV40 DNA and 1 unit of top1 per reaction. Aliquots were taken at indicated times and stopped with 0.5% SDS (final concentration). Samples were digested with 0.5 mg/ml proteinase K for 15 min at 50°, mixed with 1.1 µl of 10 × loading buffer (see above), and subjected to electrophoresis in a 1% agarose gel made in 1 × TBE buffer. The ethidium bromide (0.5 µg/ml) stained supercoiled bands were visualized using a Molecular Dynamics FluorImager and quantified with ImageQuant software.
DNA single-strand breaks, measurements by alkaline elution.
Human MCF7 breast carcinoma cells were treated with NSC 314622 or CPT
for 1 hr. Aliquots were analyzed by alkaline elution (Covey et
al., 1989
; Bertrand and Pommier, 1995
).
Cytotoxicity assays in human leukemia CEM and CPT-resistant CEM/C2 cells. Exponentially growing CEM and CEM/C2 cells were treated with NSC 314622 or CPT for the times indicated in Table 1. The cells were counted with a Coulter Electronics (Miami Lake, FL) Counter model ZBI before and 48 hr after beginning of treatment. Growth fraction was calculated relative to control (untreated cells) with control being 1.
|
| |
Results |
|---|
|
|
|---|
COMPARE analysis of NSC 314622.
NSC 314622 was selected as a
potential top1 inhibitor by COMPARE analysis in the National Cancer
Institute In Vitro Anticancer Drug Discovery Screen. The
COMPARE algorithm was developed to permit the rapid selection of
compounds with similar or novel cytotoxicity relative to established
anticancer agents with known mechanisms of action (Boyd and Paull,
1995
; Paull et al., 1995
). If the data pattern of an agent
of interest correlates well with the data patterns of one or more
agents of known mechanism of action, then the hypothesis is that the
agent of interest may have the same mechanism of action as those agents
of known mechanism. It is always necessary to confirm this hypothesis
in the laboratory. If the agent of interest has no good correlation
with a set of agents comprising most known biochemical mechanisms of
action, the hypothesis is that it has a novel mechanism. This
hypothesis is difficult to prove so it remains tentative until the
agent's mechanism is actually elucidated in the laboratory.
|
NSC 314622 induces top1-mediated DNA cleavage complexes with a
different pattern from CPT.
Induction of DNA cleavage in the
presence of top1 was tested in a fragment of the human c-myc gene (Fig.
3A) and in the
PvuII/HindIII fragment of pBluescript SK(
)
phagemid DNA (Fig. 3B). A number of cleavage sites detected in the
presence of NSC 314622 were also induced by CPT. However, NSC 314622 induced top1 sites that were not observed with CPT, but did not
stabilize all the CPT sites, and the relative cleavage intensity of
similar sites varied between NSC 314622 and CPT. Top1-induced cleavage
in the presence of NSC 314622 was detectable at 0.3 µM
and increased with increasing drug concentrations up to 100 µM. These results confirmed the COMPARE analysis that NSC
314622 is a top1 poison and suggested that the DNA cleavage patterns
induced by NSC 314622 exhibited similarities and differences from those
of CPT.
|
Top1 linkage and reversibility of the top1 cleavage complexes
induced by NSC 314622.
Top1 cleavage complexes are protein linked
(Hsiang et al., 1985
; Covey et al., 1989
), with
top1 covalently linked to the 3'-terminus of the DNA break that it
generates. Thus, with the use of 5'-end-labeled DNA, the labeled strand
is expected to become covalently linked to top1. Fig.
4A shows that treatment of 5'-end-labeled
c-myc DNA with either CPT or NSC 314622 in the presence of top1
resulted in DNA retention at the top of the gel when the proteinase K
digestion step was omitted. Treatment with proteinase K released the
high molecular-weight DNA and generated the cleaved DNA fragments (Fig. 4B). This result demonstrates that the breaks induced by NSC 314622 are
protein linked.
|
Stability of the top1 cleavage complexes induced by NSC
314622.
We also tested the induction of top1 cleavage complexes
using an oligonucleotide containing a single top1 cleavage site (Fig. 5A) (Pommier et al., 1995
). In
this system, CPT-induced DNA cleavage was seen as an increase of the
19-mer product, and after 1 hr CPT-induced DNA cleavage decreased. This
decrease could be due to inactivation of top1 or CPT lability during
the time course of the reaction. NSC 314622 also enhanced top1 cleavage
in this oligonucleotide at the same site as CPT. The cleavage complexes induced by NSC 314622 were more persistent than the cleavable complexes
induced by CPT (Fig. 5, B and C).
|
NSC 314622 inhibits top1-mediated DNA relaxation.
Top1 is very
efficient at relaxing DNA supercoiling (Champoux, 1990
; Wang, 1996
).
Relaxation of SV40 DNA by top1 was reduced at every time point by NSC
314622 when compared with the top1-mediated SV40 DNA reactions in the
absence of drug (Fig. 6). Thus, NSC 314622 inhibits top1 catalytic activity.
|
NSC 314622 does not unwind DNA.
Unwinding assay using
supercoiled DNA in the presence of top1 is a simple procedure to detect
DNA intercalation (Pommier et al., 1987
). In this assay,
excess top1 (10 units instead of the 1 unit per reaction shown in Fig.
6) is used to compensate for an eventual inhibitory effect of the drug
tested in the assay (Pommier et al., 1987
). Fig.
7 shows that NSC 314622 had no detectable effect on top1-mediated relaxation of SV40 DNA. These results suggest
that NSC 314622 is not a DNA intercalator up to a concentration of 100 µM.
|
Protein-linked DNA single-strand breaks induced by NSC 314622 in
human breast carcinoma MCF7 cells.
Drug-induced top1 cleavage
complexes were assayed in MCF7 cells by alkaline elution. Typically, in
the case of CPT (Covey et al., 1989
), top1 cleavage
complexes can be found as DNA single-strand breaks that are detectable
only after proteinase digestion of the cell lysates. Fig.
8 shows that 1 µM NSC
314622 produced approximately 300 rad-equivalent DNA single-strand
breaks and that, as in the case of CPT, these breaks were protein
associated (top 1 linked).
|
Reversal kinetics of DNA single-strand breaks induced by NSC 314622 in MCF7 cells.
As shown in Fig. 9,
CPT-induced DNA single-strand breaks were completely reversed 30 min
after the drug was removed from the cell cultures (Covey et
al., 1989
; Valenti et al., 1997
), whereas it took more
than 1 hr for the NSC 314622-induced DNA single-strand breaks to
reverse. Thus, the DNA single-strand breaks induced by NSC 314622 reversed more slowly than the breaks induced by CPT.
|
Cytotoxicity of NSC 314622 in a CPT-resistant top1-mutant cell
line.
CEM/C2 cells are highly resistant to CPT as a result of a
mutation of one of the top1 alleles, Asn722Ser (Fujimori et
al., 1995
), and inactivation of the other top1 allele(s) (Fujimori et al., 1996
). Table 2 shows
that CEM/C2 cells were cross-resistant to NSC 314622, consistent with
the possibility that top1 is a cytotoxic target of NSC 314622.
|
| |
Discussion |
|---|
|
|
|---|
DNA topoisomerases are important targets for cancer chemotherapy.
Two of the cellular topoisomerases, top2 and top1, are targeted specifically by potent anticancer drugs, although no inhibitor has been
reported for the more recently discovered third class of cellular
topoisomerases, top3 (Wang, 1996
). Top2 is the target of several of the
most effective anticancer drugs to date: the anthracyclines
(doxorubicin, daunorubicin, epirubicin, and idarubicin), the
epipodophyllotoxins etoposide (VP-16) and teniposide (VM-26), the
anthracenediones (mitoxantrone and derivatives), the ellipticines, the
acridine amsacrine and the bis-dioxopiperazines, ICRF 187 and 193 [for
review, see Pommier (1997)
]. Each of these top2 inhibitors has
preferential activity for different cancers. Hence, it is likely that
non-CPT top1 inhibitors will exhibit different anticancer activity from
camptothecins.
Several methods have been applied to the discovery of novel top1
inhibitors. Biochemical assays with top1 and purified DNA have led to
the recent discovery of several novel classes of top1 inhibitors [for
recent review see Pommier (1998)
], including actinomycin D (Trask and
Muller, 1988
; Wassermann et al., 1990
);
morpholinodoxorubicin (Wassermann et al., 1990
); saintopin
(Yamashita et al., 1991
; Leteurtre et al. 1994
);
and other benzoanthracenes, nitidine, and other benzophenanthridines
(Fang et al., 1993
; Larsen et al., 1993
);
indoloquinolinediones (Riou et al., 1991
); intoplicine (Poddevin et al., 1993
); indolocarbazoles (Yamashita
et al., 1992
; Yoshinari et al., 1995
); and
benzimidazoles (Chen et al., 1993
; Kim et al.,
1996
). Yeast strains with deletion of the top1 gene can also be a
useful screening tool because these mutants are selectively resistant
to CPT and other top1 poisons (Nitiss and Wang, 1988
; Gatto et
al., 1996
; Nitiss et al., 1997
). A third approach is
provided by the National Cancer Institute Anticancer Drug Screen and
the COMPARE analysis (Paull et al., 1989
; Boyd and Paull,
1995
; Paull et al., 1995
).
Table 1 provides a summary COMPARE listing for NSC 314622. Briefly, the
60 cell-line growth-inhibitory data obtained for NSC 314622 in the
screen was correlated in pairs with the growth-inhibitory data for more
than 60,000 compounds. The resulting list of NSC numbers and
correlation coefficients was sorted by decreasing correlation
coefficient. As shown in Table 1, portions of a list of the top 100 correlations were condensed to a single line if two or more
camptothecins came together. Fig. 2 shows the GI50 mean graph (Boyd and
Paull, 1995
; Paull, 1995
) for NSC 314622. These COMPARE data suggested
that NSC 314622 was a top1 inhibitor. We previously used COMPARE to
identify a novel top2 inhibitor, NSC 665517 (Gupta et al.,
1995a
) and to discover that azatoxins, a novel class of top2
inhibitors, exhibited antitubulin activity (Solary et al.,
1993
). COMPARE has also been used to identify p-glycoproteinMDR substrates (Lee et
al., 1994
; Alverez et al., 1995
) and new antitubulin agents (Paull et al., 1992
). The recent inclusion of a large
number of CPT derivatives in the National Cancer Institute Database and the identification of other tested agents as top1 inhibitors have provided the means to identify novel top1 inhibitors. NSC 314622 is the
first top1 inhibitor reported using COMPARE.
Our biochemical assays with purified top1 demonstrated that NSC 314622 is a top1 inhibitor. The cellular data with the top1 mutant and
CPT-resistant CEM/C2 cell line (Fujimori et al., 1995
, 1996
)
also are consistent with the hypothesis that NSC 314622 targets top1 in
cells. Top1 inhibition by NSC 314622 exhibits some differences from
CPT. First, some of the drug-induced cleavage sites seemed different.
Some sites were more intense with NSC 314622, whereas others were more
intense with CPT. Such differences may be important in cells because
some genes may be more selectively targeted by one compound than the
other. Second, the top1 cleavage complexes trapped by NSC 314622 seemed
more persistent than those induced by CPT in MCF7-treated cells (Fig.
9) and with purified enzyme (Fig. 5). This might offer an advantage for
cancer chemotherapy because the rapid reversibility of the CPT-induced
cleavage complexes imposes long infusions of CPTs to achieve maximum
activity (Pommier, 1996
). Third, NSC 314622 differs from CPTs in that
NSC 314622 is chemically more stable than CPT. At physiological, and
even more readily at alkaline pH, the lactone E ring of CPTs is
hydrolyzed to the carboxylate form, which has no detectable activity
against purified top1 (Jaxel et al., 1989
). Thus, it seems
that NSC 314622 is a lead compound for developing novel non-CPT top1
inhibitors.
Most of the other non-CPT top1 inhibitors reported to date [see above
and, for review, see Pommier (1998)
] are DNA intercalators or minor
groove binders. Our unwinding assay data suggested that NSC 314622 did
not intercalate into DNA. The fact that the top1 cleavage complexes
were not inhibited at high drug concentrations is also consistent with
lack of strong DNA intercalation for NSC 314622.
| |
Acknowledgments |
|---|
This article is dedicated to the memory of Dr. Ken Paull.
| |
Footnotes |
|---|
Received December 17, 1997; Accepted March 27, 1998
Send reprint requests to: Dr. Yves G. Pommier, Lab of Molecular Pharmacology, Division of Basic Sciences, NCI, NIH, Building 37, Room 5D02, Bethesda, MD 20892-4255. E-mail: pommier{at}nih.gov
| |
Abbreviations |
|---|
CPT, camptothecin; top, topoisomerase; bp, base pair(s); DMSO, dimethylsulfoxide; GI50, growth inhibition 50% concentrations; NSC 314622, 5,6-dihydro-5,11-diketo-2,3-dimethoxy-6-methyl-8,9-methylenedioxy-11H-indeno(1,2-c)isoquinoline ; PCR, polymerase chain reaction; SDS, sodium dodecyl sulfate; SV40, simian virus 40; TBE, Tris/borate/EDTA.
| |
References |
|---|
|
|
|---|
-D-glucopyranosyl)-5H-indolo[2, 3-a] pyrrolo[3,4-c] carbazole-5,7(6H)-dione (NB-506): induction of topoisomerase I-mediated DNA cleavage and mechanisms of cell line-selective cytotoxicity.
Cancer Res
55:
1310-1315This article has been cited by other articles:
![]() |
S. Antony, K. K. Agama, Z.-H. Miao, K. Takagi, M. H. Wright, A. I. Robles, L. Varticovski, M. Nagarajan, A. Morrell, M. Cushman, et al. Novel Indenoisoquinolines NSC 725776 and NSC 724998 Produce Persistent Topoisomerase I Cleavage Complexes and Overcome Multidrug Resistance Cancer Res., November 1, 2007; 67(21): 10397 - 10405. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. G. Covell, R. Huang, and A. Wallqvist Anticancer medicines in development: assessment of bioactivity profiles within the National Cancer Institute anticancer screening data Mol. Cancer Ther., August 1, 2007; 6(8): 2261 - 2270. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Antony, K. K. Agama, Z.-H. Miao, M. Hollingshead, S. L. Holbeck, M. H. Wright, L. Varticovski, M. Nagarajan, A. Morrell, M. Cushman, et al. Bisindenoisoquinoline Bis-1,3-{(5,6-dihydro-5,11-diketo-11H-indeno[1,2-c]isoquinoline)-6-propylamino}propane bis(trifluoroacetate) (NSC 727357), a DNA Intercalator and Topoisomerase Inhibitor with Antitumor Activity Mol. Pharmacol., September 1, 2006; 70(3): 1109 - 1120. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Marchand, S. Antony, K. W. Kohn, M. Cushman, A. Ioanoviciu, B. L. Staker, A. B. Burgin, L. Stewart, and Y. Pommier A novel norindenoisoquinoline structure reveals a common interfacial inhibitor paradigm for ternary trapping of the topoisomerase I-DNA covalent complex. Mol. Cancer Ther., February 1, 2006; 5(2): 287 - 295. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Antony, G. Kohlhagen, K. Agama, M. Jayaraman, S. Cao, F. A. Durrani, Y. M. Rustum, M. Cushman, and Y. Pommier Cellular Topoisomerase I Inhibition and Antiproliferative Activity by MJ-III-65 (NSC 706744), an Indenoisoquinoline Topoisomerase I Poison Mol. Pharmacol., February 1, 2005; 67(2): 523 - 530. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. CHAN, S. N. KHAN, I. HARVEY, W. MERRICK, and J. PELLETIER Eukaryotic protein synthesis inhibitors identified by comparison of cytotoxicity profiles RNA, March 1, 2004; 10(3): 528 - 543. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Facompre, C. Tardy, C. Bal-Mahieu, P. Colson, C. Perez, I. Manzanares, C. Cuevas, and C. Bailly Lamellarin D: A Novel Potent Inhibitor of Topoisomerase I Cancer Res., November 1, 2003; 63(21): 7392 - 7399. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Antony, M. Jayaraman, G. Laco, G. Kohlhagen, K. W. Kohn, M. Cushman, and Y. Pommier Differential Induction of Topoisomerase I-DNA Cleavage Complexes by the Indenoisoquinoline MJ-III-65 (NSC 706744) and Camptothecin: Base Sequence Analysis and Activity against Camptothecin- Resistant Topoisomerases I Cancer Res., November 1, 2003; 63(21): 7428 - 7435. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. M. Smith, A. Kazi, L. Smith, T. E. Long, B. Heldreth, E. Turos, and Q. P. Dou A Novel beta -Lactam Antibiotic Activates Tumor Cell Apoptotic Program by Inducing DNA Damage Mol. Pharmacol., June 1, 2002; 61(6): 1348 - 1358. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. L. Beretta, M. Binaschi, E. Zagni, L. Capuani, and G. Capranico Tethering a Type IB Topoisomerase to a DNA Site by Enzyme Fusion to a Heterologous Site-selective DNA-binding Protein Domain Cancer Res., August 1, 1999; 59(15): 3689 - 3697. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Takebayashi, P. Pourquier, A. Yoshida, G. Kohlhagen, and Y. Pommier Poisoning of human DNA topoisomerase I by ecteinascidin 743, an anticancer drug that selectively alkylates DNA in the minor groove PNAS, June 22, 1999; 96(13): 7196 - 7201. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. W. Zaharevitz, R. Gussio, M. Leost, A. M. Senderowicz, T. Lahusen, C. Kunick, L. Meijer, and E. A. Sausville Discovery and Initial Characterization of the Paullones, a Novel Class of Small-Molecule Inhibitors of Cyclin-dependent Kinases Cancer Res., June 1, 1999; 59(11): 2566 - 2569. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. F. Frohlich, S. Gude Hansen, M. Lisby, I. Grainge, O. Westergaard, M. Jayaram, and B. R. Knudsen Inhibition of Flp Recombinase by the Topoisomerase I-targeting Drugs, Camptothecin and NSC-314622 J. Biol. Chem., March 2, 2001; 276(10): 6993 - 6997. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||